Unraveling the Complexities of Menopause Management

PLEASE NOTE:
As required by the ACCME, all participants must read the information below before proceeding to this activity.
After doing so, please click the Launch Activity button at the bottom of this page.
 

PROGRAM DIRECTORS


Richard J. Santen, MD
Professor of Internal Medicine
Associate Director, Clinical
   Research
University of Virginia Health System
Charlottesville, Virginia
 

Nanette F. Santoro, MD
Professor and Director
Department of Obstetrics &
  Gynecology and Women’s
  Health
Division of Reproductive
  Endocrinology
Albert Einstein College of Medicine
Bronx, New York


FACULTY


William H. Catherino, MD, PhD
Research Director
Department of Obstetrics and
  Gynecology
Uniformed Services University
  of the Health Sciences
Research Director
Director of Reproductive
  Endocrinology (Intramural)
National Institute of Child
  Health & Human Development
Bethesda, Maryland


Marcelle I. Cedars, MD
Director
Division of Reproductive
  Endocrinology
University of California,
  San Francisco
Women’s Health—Mount Zion
San Francisco, California


S. Mitchell Harman, MD, PhD
Director and President
Kronos Longevity Research
  Institute
Phoenix, Arizona


Kathryn A. Martin, MD
Assistant Professor of Medicine
Harvard Medical School
Co-Director, Reproductive   Endocrine Associates
Massachusetts General Hospital
Senior Deputy Editor,   Endocrinology and Diabetes
Up-To-Date
Boston, Massachusetts


Donald P. McDonnell, PhD
Professor of Pharmacology
   and Cancer Biology
Director of Graduate Studies,   Pharmacology
Duke University Medical Center
Durham, North Carolina


Lubna Pal, MBBS, MRCOG, MS
Assistant Professor
Department of Obstetrics, Gynecology and Reproductive   Sciences
Yale University School of Medicine
New Haven, Connecticut


Régine L. Sitruk-Ware, MD
Executive Director,
  Research and Development
Population Council
New York, New York


Cynthia A. Stuenkel, MD
Clinical Professor of Medicine
Departments of Endocrine-Metabolism and
  Family and Preventive Medicine
University of California, San Diego
School of Medicine
La Jolla, California


This CME activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME/CE activities may not contain the most up-to-date information available.

Click here to view current CME activities.


ACTIVITY AGENDA

Professional Exchange Lectures (30 minutes)

  • Critical Issue of Disentangling Menopause From Aging
    S. Mitchell Harman, MD, PhD
    Nanette F. Santoro, MD

  • Applying an Understanding of the Mechanisms of Action of Estrogen and SERMs to Patient and Treatment Selection in Clinical Practice
    Donald P. McDonnell, PhD

  • Putting the WHI into Clinical Perspective
    Cynthia A. Stuenkel, MD

  • Are All SERMs the Same?
    William H. Catherino, MD, PhD
    Régine L. Sitruk-Ware, MD

 Mini Lecture Series (15 minutes)

  • Selecting Candidates for Fracture Prevention Based on Risk Prediction
    Lubna Pal, MBBS, MRCOG, MS

  • Efficacy and Safety Profiles of New and Emerging Menopause Treatments
    Kathryn A. Martin, MD

  • Future Treatment Strategies for Menopausal Symptom Management
    Richard J. Santen, MD

  • Starting and Stopping Hormone Therapy
    Marcelle I. Cedars, MD

top


LEARNING OBJECTIVES

  • Assess the potential role of ET, HT, and SERMs in treatment regimens in menopausal women utilizing an understanding of estrogen receptors, estrogen signaling pathways, and selectivity.

  • Assess the mechanisms of action, efficacy, safety, and clinical/patient considerations of ET, HT, and SERM therapies to develop customized therapeutic interventions for menopausal women that improve their outcomes.

  • Evaluate the potential burden of disease resulting from menopause.

  • Assess the pros and cons of ET and HT therapy based on the most recent insights into the WHI study analyses and patient selection criteria for these agents to integrate therapies into successful treatment regimens for optimal outcomes in menopausal patients.

  • Differentiate the selectivity, potency, and mechanisms of action of current and emerging SERMs to identify the optimal SERM profile for customized therapy for menopausal patients.

  • Utilize an understanding of ET, HT, and SERM therapy-related side effects to develop interventions that minimize side effects in order to maintain patients on therapy with optimal QOL.

top


Accreditation

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Endocrine Society designates this educational activity for a maximum of 2.75 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Statement of Independence

As an accredited provider of continuing medical education (CME), it is The Endocrine Society’s policy to ensure that the contents and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Special Programs Committee of The Endocrine Society. The commercial supporters of this activity have no influence over the selection of the faculty or specific presentations.

The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of The Endocrine Society.


Disclosure Policy

The faculty, committee members, and staff involved in planning this CME activity are required to disclose to the learners all relevant financial relationship(s) with any commercial interest that have occurred within the last 12 months. Such relationships may include grants, research support or participation in industry-sponsored research, stock ownership, employment, consultation, or participation in speakers’ bureaus and boards of directors. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

Disclosure Information

The following faculty reported no relevant financial relationship and/or conflicts of interest:

William H. Catherino, MD, PhD
Marcelle I. Cedars, MD
S. Mitchell Harman, MD, PhD
Kathryn A. Martin, MD
Lubna Pal, MBBS, MRCOG, MS
Régine L. Sitruk-Ware, MD

The following faculty reported relevant financial relationships and/or conflicts of interest:

Donald P. McDonnell, PhD, has received research support from and served on the advisory board for Wyeth Pharmaceuticals.

Richard J. Santen, MD, has received honorarium for serving in medical advisory boards for Wyeth Pharmaceuticals and Novo Nordisk.

Nanette F. Santoro, MD, has received grant support from Ferring Pharmaceuticals, Inc; has received consulting fees from and served on the advisory board for Wyeth Pharmaceuticals; and served on the advisory board for QuatRx.

Cynthia A. Stuenkel, MD, has received honorarium from Wyeth Pharmaceuticals, Upsher-Smith Laboratories, Inc, and Ally Pharma Options Pvt. Ltd.

Endocrine Society staff associated with the development of this program reported no relevant financial relationship and/or conflicts of interest.

Projects In Knowledge staff associated with the development of this program reported no relevant financial relationship and/or conflicts of interest.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Wyeth Pharmaceuticals.

top

 


Requires Flash 8 or higher
and high-speed internet 

 
 
 
 


Copyright © 1997-2017, Projects In Knowledge, Inc. All rights reserved.
PROJECTS IN KNOWLEDGE • Overlook at Great Notch • 150 Clove Road, 10th Floor • Little Falls, New Jersey 07424 (973) 890-8988

For questions or comments regarding this web site please contact: Webmaster
Privacy Policy

 

Release Date:
   July 15, 2008.

Termination Date:
   July 15, 2009.

Estimated time for completion of this activity: 2.75 hours

This independent CME activity is supported by an educational grant from Wyeth Pharmaceuticals.



1833